Search
Now showing items 1-10 of 13
Chapter 7: Responses to health correlates and consequences.
(UK Focal Point on Drugs at Public Health England, 2013-12-16)
Chapter 6: Health correlates and consequences
(UK Focal Point on Drugs at Public Health England, 2013-12-16)
The Unregulated Psychoactive Compound: ‘Benzo Fury’
(2013-12)
Introduction: The ‘legal high’ ‘Benzo Fury’ [1-(benzofuran-5-yl)propan-2-amine (5-APB) and 1-(benzofuran-6-yl)propan-2-amine (6-APB)] is an unregulated psychoactive compound which has similar effects as known controlled ...
Factors Impacting on the Evolution and Characteristics of UK Deaths Involving‘Traditional’ and ‘New’ Stimulants.
(2013-12)
Introduction: This presentation outlines recent changes in UK drug indicators in respect of ‘traditional’ stimulants (amphetamine, cocaine, ecstasy) and how these may have influenced the ever-quickening emergence of ‘new’ ...
Methoxetamine: An Analogue of Ketamine
(2013-12)
Introduction: Methoxetamine acts similarly to a non-competitive antagonist at the N-methyl-aspartate receptor and a Dopamine reuptake inhibitor. Its behavioural effects resemble those induced by dissociative anesthetics, ...
Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse
(2013-12)
Background and objective. Despite animal studies having shown a generalisation of the bupropion cue to cocaine, this drug has been used in cocaine abuse with mixed results. We here aimed at describing two cases which ...
Fatalities Associated with Mephedrone in Combination with Other Stimulant Drugs in Young People Aged 16-24 Years
(2013-12)
Introduction: Mephedrone is a stimulant Class B drug chemically related to amphetamine. It comes in tablet or powder form and has no therapeutic use. Mephedrone’s reported effects are similar to those of amphetamine and ...
UK deaths associated with ‘Z’ drugs (Zopiclone, Zolpidem & Zaleplon)
(Advisory Council on the Misuse of Drugs, 2013-09-05)
Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances (NPS) in the EU : the outcomes of the ReDNet project
(2013-07-25)
Objectives: The recent emergence of new psychoactive compounds (NPS) has raised prominent challenges in the fields of drug policy, substance use research, public health and service provision. The Recreational Drugs European ...
MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity : a brief overview and update
(2013-07-25)
Objectives MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) is a psychoactive substance, sold primarily over the Internet and in ‘head’ shops as a ‘legal ...